[SMLE] Lambert-Eaton myasthenic syndrome

[RSS-Bot]

Handb Clin Neurol. 2024;200:307-325. doi: 10.1016/B978-0-12-823912-4.00012-8.

ABSTRACT

Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disease characterized by proximal muscle weakness, loss of tendon reflexes, and autonomic dysfunction. Muscle weakness usually starts in the upper legs and can progress to oculobulbar and in severe cases respiratory muscles. P/Q-type voltage-gated calcium channels (VGCCs) localized in the presynaptic motor nerve terminal and in the autonomic nervous system are targeted by antibodies in LEMS patients. These antibodies can be detected in about 90% of patients, and the presence of decrement and increment upon repetitive nerve stimulation is also a highly sensitive diagnostic test. Rapid diagnosis is important because of the association with SCLC in 50%-60% of patients, which stresses the need for vigorous tumor screening after diagnosis. Clinical parameters can predict tumor probability and guide frequency of tumor screening. Treatment of the tumor as well as symptomatic treatment and immunosuppression can effectively control symptoms in the majority of patients.

PMID:38494285 | DOI:10.1016/B978-0-12-823912-4.00012-8


Source: https://pubmed.ncbi.nlm.nih.gov/3849428 ... t9+e462414